BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37366654)

  • 1. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review.
    Khanam R; Ashruf OS; Waqar SHB; Shah Z; Batool S; Mehreen R; Pachika P; Roksana Z; Rehman MEU; Anwer F
    Antibodies (Basel); 2023 May; 12(2):. PubMed ID: 37366654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 3. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis.
    Noori M; Yazdanpanah N; Rezaei N
    Cancer Cell Int; 2023 Sep; 23(1):193. PubMed ID: 37670301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
    Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
    Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
    Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.
    Gao X; Zeng H; Zhao X; Wu H; Yan M; Li Y; Zhang G; Sun F
    BMC Cancer; 2023 Nov; 23(1):1058. PubMed ID: 37924016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
    Einsele H; Moreau P; Bahlis N; Bhutani M; Vincent L; Karlin L; Perrot A; Goldschmidt H; van de Donk NWCJ; Ocio EM; Martinez-Lopez J; Rodríguez-Otero P; Dytfeld D; Diels J; Strulev V; Haddad I; Renaud T; Ammann E; Cabrieto J; Perualila N; Gan R; Zhang Y; Parekh T; Albrecht C; Weisel K; Mateos MV
    Adv Ther; 2024 Apr; 41(4):1576-1593. PubMed ID: 38402374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
    Shirouchi Y; Maruyama D
    Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
    D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
    J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
    Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
    Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
    Moreau P; Mateos MV; Gonzalez Garcia ME; Einsele H; De Stefano V; Karlin L; Lindsey-Hill J; Besemer B; Vincent L; Kirkpatrick S; Delforge M; Perrot A; van de Donk NWCJ; Pawlyn C; Manier S; Leleu X; Martinez-Lopez J; Ghilotti F; Diels J; Morano R; Albrecht C; Strulev V; Haddad I; Pei L; Kobos R; Smit J; Slavcev M; Marshall A; Weisel K
    Adv Ther; 2024 Feb; 41(2):696-715. PubMed ID: 38110653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.